Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry and the pricing of prescription drug products.
All entries for: Ophthalmology
March 18, 2026
4D Molecular Therapeutics
Neutral Outlook
Emeryville, CA
201-500 employees
While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Ophthalmology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic
March 17, 2026
Kalaris Therapeutics
Negative Outlook
Palo Alto, CA
1-50 employees
Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.
Disease Area: Ophthalmology
Drug Type: Biologic